Swiss National Bank Prelude Therapeutics Inc Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$4.0 - $7.55 $118,800 - $224,235	-29,700 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$6.9 - $13.22 $15,180 - $29,084	2,200 Added 8.0%	29,700 $205,000
Q4 2021 Feb 08, 2022	BUY	$11.89 - $31.74 $83,230 - $222,180	7,000 Added 34.15%	27,500 $342,000
Q2 2021 Aug 06, 2021	BUY	$28.63 - $44.3 $586,915 - $908,149	20,500 New	20,500 $587,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.